Additionally, tyrosine kinase inhibitors (TKI), such as imatinib, interfere with signal transduction and angiogenesis, causing cardiotoxic effects, particularly in treatments for HER2-positive breast cancer [20]. This evidence concerns the gene ERBB2 and breast carcinoma.